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ABSTRACT.
Purpose: Of the antioxidants found in the human retina, only the macular carotenoid quantities can be estimated noninvasively (albeit in a collective fashion),
thus facilitating study of their role in that tissue. The aim of this study was to
evaluate concordance between macular pigment optical density (MPOD) values
recorded on a commercially available instrument, the MPS 9000, with those of
an already validated heterochromatic ﬂicker photometry instrument. Also, we
assessed and compared test–retest variability for each instrument.
Methods: Macular pigment optical density at 0.5 retinal eccentricity was measured using two different heterochromatic ﬂicker photometers, the MPS 9000
and the Macular DensitometerTM, in 39 healthy subjects. Test–retest variability was evaluated separately for each instrument by taking three readings over
a 1-week period in 25 subjects.
Results: There was a moderate positive correlation for MPOD at 0.5 of retinal eccentricity between the MPS 9000 and the Macular Densitometer
described by the linear equation y = 0.763x + 0.172 (r = 0.68, p < 0.001,
r2 = 0.46); however, a paired-samples t-test showed a signiﬁcant difference in
terms of mean values, with a bias of lower MPOD values being yielded by the
MPS 9000 (t = )4.103, p < 0.001). Bland–Altman analysis indicated only
moderate agreement between the two instruments, reﬂected in 95% limits of
agreement of 0.1 ± 0.27. Inter-sessional repeatability, expressed as a coefﬁcient of repeatability, ranged from 0.18 to 0.21 [mean (±SD): 0.19 (0.02)] for
the MPS 9000 and from 0.11 to 0.12 [mean (±SD): 0.12 (0.01)] for the Macular Densitometer.
Conclusion: The results demonstrate that the MPS 9000 consistently yields
MPOD readings, which are lower than that found with the Macular Densitometer, and exhibits substantial test–retest variability.
Key words: age-related macular degeneration – heterochromatic ﬂicker photometry – Macular
Densitometer – macular pigment – MPS 9000
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Introduction
Age-related macular degeneration
(AMD) is the most frequent cause of
blindness among individuals ‡55 years
in developed countries (Leibowitz
et al. 1980; Attebo et al. 1996; Friedman et al. 2004), and with increasing
longevity, the incidence of AMD is rising. The therapeutic options for AMD
are limited, though improving, in particular for neovascular AMD. (Ciulla
et al. 1988; Macular Photocoagulation
Study Group 1993; Avery et al. 2006).
Although vision loss with neovascular
AMD is more sudden and severe, the
non-neovascular forms, including the
atrophic type, are more prevalent and
account for approximately 90% of
cases (Richer et al. 2004). At present,
there is no consensus with respect to
the management (including risk analysis and ⁄ or prevention) of these more
common non-neovascular forms of the
condition, which may, at least partly,
reﬂect our incomplete understanding of
AMD’s aetiopathogenesis.
In the absence of effective treatment
strategies for non-neovascular AMD,
interest has focused on prevention
and ⁄ or retardation of progression.
Macular pigment (MP), composed of
lutein (L) and zeaxanthin (Z), two hydroxycarotenoids, which are entirely
of dietary origin (Bone et al. 1997;
Johnson et al. 2005) and the retinal
metabolite of L; meso-Zeaxanthin
(meso-Z), is believed to be associated
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with reduced risk of development and
progression of AMD. Macular pigment can be augmented, not only by
eating food rich in these carotenoids,
such as spinach, but also by dietary
fortiﬁcation with one of the many
commercially available food supplements (Bone et al. 2003; Connolly
et al. 2010). Epidemiological studies
have observed an inverse association
between the prevalence of AMD and
a diet rich in L and Z (Eye Disease
Case-Control Study Group 1993; Seddon et al. 1994), and furthermore,
eyes with AMD have typically been
shown to exhibit signiﬁcantly lower
levels of MP when compared to those
without AMD (Eye Disease CaseControl Study Group 1993; Beatty
et al. 2001; Bone et al. 2001; Bernstein
et al. 2010), although this relationship
was not observed in the Muenster
Aging and Retina Study (Dietzel et al.
2011).
The putative capacity of MP to play
a role in preventing or retarding the
progression of AMD rests on its ability to limit photo-oxidative injury in
the inner retina through its prereceptoral absorption of short wavelength
light (Snodderly et al. 1984a,b; Snodderly 1995) and ⁄ or the antioxidant
properties of these carotenoids as they
act as free radical scavengers in the
retina (Snodderly 1995). The optical
density and spatial distribution of MP
have been shown to vary dramatically
between individuals (Pease et al. 1987;
Bone et al. 1992; Hammond et al.
1995), with consequential large interindividual variation in prereceptoral
short wavelength light absorption and
antioxidant activity in the retina.
Several methods for measuring the
optical density of MP have been
developed, thereby enabling investigators and ⁄ or eye care professionals to
detect changes in MP concentration
and distribution over time and therefore monitor the response to dietary
modiﬁcation or fortiﬁcation. Unsurprisingly, there is a growing demand
for a valid, reproducible, user-friendly
instrument that measures macular pigment optical density (MPOD).
Heterochromatic ﬂicker photometry
(HFP) was the ﬁrst, and remains the
most widely used, technique for measuring MPOD in vivo (Snodderly et al.
1984a,b; Pease et al. 1987; Hammond
et al. 1997, 2005; Berendschot et al.
2003; Nolan et al. 2008; Rougier et al.

2008; Stringham et al. 2008). Heterochromatic ﬂicker photometry is a psychophysical method, which requires
the subject to make iso-luminance
matches between green (not absorbed
by MP) and blue (strongly absorbed
by MP) ﬂickering lights, which is typically perceived as the point of cessation (or detection) of ﬂicker. The
technique typically employs a stimulus-surround conﬁguration, where the
stimulus consists of a target presented
in counterphase ﬂicker (alternating
blue to green). The log ratio of the
amount of blue light absorbed centrally, where MP peaks, to that
absorbed at a peripheral retinal locus
gives a measure of the individual’s
MPOD. This method has been validated against the absorption spectrum
of MP in vitro (Bone et al. 1992;
Hammond et al. 2005). The MPS
9000 is a relatively new HFP instrument that has been developed for clinical use (van der Veen et al. 2009). It
is evident from the literature, however, that while based on the same
basic optical principles of HFP, significant design and methodological differences do exist. We report a
concordance study between the newly
available commercial instrument, the
MPS 9000, and the validated and conventional research instrument for measuring
MPOD,
the
Macular
Densitometer. We also measured and
compared the inter-sessional repeatability for the two instruments.

Materials and Methods
This study was conducted at Dublin
Institute of Technology (DIT), Dublin, Republic of Ireland. Eighty-nine
subjects, aged 21–61 years, were
recruited by word of mouth and were
randomly assigned to either the concordance [39 subjects; mean age 29
(±11)] or repeatability [50 subjects;
mean age 34 (±10)] arms of the
study. Informed consent was obtained
from each volunteer after the provision of a detailed information sheet.
Ethical approval was granted by the
research ethics committee at DIT, and
the experimental procedures adhered
to the Declaration of Helsinki. Inclusion criteria required participants to
be aged 18 years or older, have no
clinical signs of ocular pathology and
have logMAR visual acuity (VA) of
better than 0.2 in the study eye. All

subjects were naı̈ve to both the instruments and to the process of measurement of MP.
The study eye was selected on the
basis of corrected distance visual acuity
(CDVA); the eye with the better CDVA
being selected, and in cases of equal
CDVA, the dominant eye was selected.
A computer-generated LogMAR test
chart (Test Chart 2000 Pro; Thompson
Software Solutions, 74 Pine Grove,
Hatﬁeld, AL97BW, UK) was used to
determine CDVA at a viewing distance
of 4 m, using a Sloan ETDRS letterset.
Subjects were requested to wear nontinted normal distance correction spectacles, if required. An ocular health
examination was conducted to rule out
any ocular pathology.
Macular pigment optical density was
measured at 0.5 eccentricity on each
instrument, on the same day, in 39
subjects to determine instrument concordance. To assess test–retest variability for each instrument, 25 subjects
had MPOD measured on three occasions over a 1-week period on each
instrument, 50 subjects were recruited
for this part of the investigation, 25
were randomly assigned to the MPS
9000 and 25 were randomly assigned
to the Macular Densitometer. All data
were collected by a single operator.
The instruments used in this study
were the MPS 9000, (Tinsley Precision
Instruments Ltd, Croyden, Essex,
UK), and the Macular Densitometer
(Macular Metrics II, Rehoboth, MA,
USA). The instrument used ﬁrst in the
concordance arm of the study was
randomly selected on a case-by-case
basis to minimize the risk of introducing bias attributable to a learning or
fatigue effect from either instrument.

MPS 9000
(M|POD⁄QuantifEYE)
The MPS 9000 is a small, portable
HFP instrument, capable of measuring MPOD at a single retinal locus
(0.5 retinal eccentricity). The instrument uses a foveal target of 1 diameter (edge located at 0.5 retinal
eccentricity) with the reference location at 8 retinal eccentricity (van der
Veen et al. 2009). Testing was carried
out according to the manufacturer’s
instructions. Prior to the ﬁrst session,
a short practice test was carried out
to familiarize the participant with the
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technique. Once the subject successfully completed the practice run, the
subject’s sensitivity to ﬂicker was
determined by a built in pretest routine, which enabled the appropriate
initial luminance contrast of the two
light sources to be established. This
short (30 seconds) pretest ﬂicker sensitivity routine was used to ensure the
participants were in the middle of
their ﬂicker sensitivity range when
performing the main task, as ﬂicker
sensitivity varies between individuals.
During the main test, the frequency
of the blue (465 nm) and green
(530 nm) light sources were automatically ramped down from 55 Hz for a
series of luminance ratios of the two
light sources. Initially, the observer
viewed the target centrally and pressed
a button when ﬂicker was detected.
This sequence of obtaining a ﬂicker
threshold for each blue-to-green ratio
continued until a ﬂicker response
curve was obtained, where the minimum represents the equalization of
the blue and green luminance. The
procedure of obtaining the ﬂicker
detection for a series of blue-to-green
ratios was repeated, after an additional short practice run, for peripheral viewing, with the subject ﬁxating
a red disc at a reference point of 8
horizontal eccentricity. The central
and peripheral minima were used to
calculate MPOD. The formation of
the central and peripheral ﬂicker
response curves was monitored by the
experienced examiner throughout the
course of the examination to ensure
reliability of the results based on the
formation of a characteristic curve
shape. Macular pigment optical density was calculated on the basis of a
single, reliable measurement using
both the central and peripheral stimuli. If a reliable measurement could
not be obtained, the subject was reinstructed and afforded one additional
and immediate opportunity to provide
a reliable result. Failure to achieve a
reliable result within two such measurement cycles resulted in exclusion
from the study.

Macular Densitometer
The Macular Densitometer is a validated MPOD measurement instrument capable of determining a spatial
proﬁle of MP, by the measurement of
MPOD at various retinal eccentricities
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between 0.25 and 3 (Wooten et al.
1999). For the purpose of this study,
readings were taken centrally at 0.50
using a 1 disc, [commonly used as it
has been shown to have the highest
repeatability of results (Snodderly
et al. 2004)], matching that used in the
MPS 9000, and a reference location at
7 using a 2 target (van der Veen
et al. 2009). The Macular Densitometer was calibrated daily, and testing
was carried out according to the manufacturer’s instructions.
Prior to using the Densitometer, all
subjects were shown an explanatory
video describing the method for
recording null ﬂicker matches. The
subject’s critical ﬂicker frequency
(CFF) was then measured, and the
optimal ﬂicker frequency (OFF) determined using a deﬁned test algorithm
designed
to
minimize
variance
between readings, in a process that
has become known as customized
HFP. If a subject could not reach null
ﬂicker, the investigator increased the
ﬂicker frequency in increments of
1 Hz, until null ﬂicker was perceived.
Alternatively, if a subject exhibited a
wide variation in null ﬂicker readings
(>10% of mean radiance at null
ﬂicker), the ﬂicker frequency was
decreased in increments of 1 Hz, until
an acceptable null ﬂicker range was
achieved. An acceptable null ﬂicker
range was deﬁned as one where the
null ﬂicker radiance values achieved
by the subject were within 5% of the
mean null ﬂicker radiance at that test
locus. Once the OFF was determined,
the subject was required to ﬁnd the
middle zone of no ﬂicker by turning a
dial that adjusts the ratio of blue
(458 nm) to green (530 nm). The
desired end-point when using the Densitometer was a point of zero or ‘null’
ﬂicker. For a detailed description of
each instrument and instructions for
use, please refer to van der Veen et al.
(2009) and Wooten et al. (1999).
Statistical analysis

The statistical software package spss
18.0 for windows was used for data
analysis. Mean MPOD for the MPS
9000 and the Macular Densitometer
was compared using paired-samples
t test. Bland–Altman analysis and
plots, as well as the limits of agreement, were used to quantify the agreement between the two instruments.

Inter-sessional
repeatability
is
expressed as a coefﬁcient of repeatability, which was calculated as the
standard deviation of the mean difference between measurements, and multiplied by 1.96. Coefﬁcients of
repeatability were calculated for (visit
1–visit 2), (visit 2–visit 3) and (visit
1–visit 3) for each instrument. A oneway repeated measures anova was
conducted to test for a learning or
fatigue effect that might confound the
test–retest analysis.

Results
The data were analysed (i) to compare
measurements taken at 0.5 on the two
instruments and (ii) to assess inter-sessional repeatability of each instrument.
Two subjects were excluded from the
instrument concordance analysis, and
one subject from the instrument intersessional repeatability analysis, on the
basis that they were deemed unable to
perform the MPS 9000 task satisfactorily on the initial or repeat assessments. Data analysis is conducted and
presented for the remaining 37 subjects
in the concordance analysis, and 49
subjects in the inter-sessional repeatability analysis.
Instrument concordance

A scatterplot, graphically representing
the relationship between MPOD values at 0.5 eccentricity obtained with
each instrument, is shown in Fig. 1
(r = 0.68, p < 0.001).
A paired-samples t-test comparing
the mean MPOD, as measured on
each instrument, yielded a statistically
signiﬁcant difference between instruments (t = )4.103, p < 0.001), demonstrating a bias of lower MPOD
values obtained on the MPS 9000,
reﬂected in an average difference in
MPOD values of 0.1 log unit between
the two instruments (Fig. 2). The 95%
limits of agreement between instruments were 0.1 ± 0.27.
Inter-sessional repeatability

A one-way repeated measures anova
was conducted to assess repeat
MPOD measurements for a learning
or fatigue effect for each instrument.
Mauchly’s test of sphericity was not
signiﬁcant (p > 0.05) for either
instrument. There was no signiﬁcant
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Fig. 1. Relationship between macular pigment optical density readings at 0.5 retinal eccentricity obtained with each instrument, with the line y = x superimposed.

Fig. 2. Bland–Altman plot for macular pigment optical density values at 0.5 retinal eccentricity, showing 95% limits of agreement between the MPS 9000 and Macular Densitometer.

difference in repeat MPOD measurements for either the MPS 9000 or the
Macular Densitometer, indicating the
absence of any learning or fatigue
effect [MPS 9000 (F = 0.09, p =
0.92); Macular Densitometer (F =
2.556, p = 0.09)]. Given that the
p value for the Macular Densitometer is
close to signiﬁcance, a post hoc pairedsamples t test was conducted comparing
visit 1 and visit 3. No signiﬁcant difference between the initial and ﬁnal measurements was observed (t = 0.000,
p = 0.999), providing further reassurance of the absence of a meaningful
learning effect using this device.
A Bland–Altman plot was constructed to assess agreement between
repeat measures taken on the MPS

9000 (Fig. 3). The coefﬁcient of
repeatability for the MPS 9000 ranged
from 0.18 to 0.21 (mean 0.19 ± 0.02;
see Table 1).
A Bland–Altman plot was also constructed to assess agreement between
repeat measures taken on the Densitometer (Fig. 4). The coefﬁcient of
repeatability for the Macular Densitometer ranged from 0.11 to 0.12
(mean 0.12 ± 0.01; see Table 1).
Inter-sessional repeatability results for
each instrument are presented in
Table 1.

Discussion
The Macular Densitometer has been
validated in previous studies (Wooten

et al. 1999; Snodderly et al. 2004;
Stringham et al. 2008), and the HFP
technique for measuring MPOD has
also been validated against the
absorption spectrum of MP in vitro
(Bone et al. 1992; Hammond et al.
2005). The MPS 9000 is a new commercial technology designed to measure MPOD and employs the HFP
technique. Despite the use of HFP,
the validity of this novel instrument
has yet to be determined, and as such,
the current study, which assesses the
accuracy and repeatability of this new
commercial instrument in relation to
the current research standard HFP
instrument, the Macular Densitometer
is timely and necessary.
In the current study, mean MPOD
was 0.32 (±0.15) for the MPS 9000
and 0.42 (±0.18) for the Macular
Densitometer, values that are consistent with previous studies (Ciulla et al.
2001; Snodderly et al. 2004; Loane
et al. 2007; Nolan et al. 2008; Makridaki et al. 2009; Bartlett et al. 2010;
Loughman et al. 2010). The correlation between the MPS 9000 and the
Macular Densitometer in this study
was found to be positive, statistically
signiﬁcant, and similar to that previously reported comparing the MPS
9000 to the Macular Pigment Reﬂectometer (van der Veen et al. 2009).
However, the mean difference between
instruments was statistically signiﬁcant, with a bias of lower MPOD in
association with the MPS 9000,
reﬂected in 95% limits of agreement
of 0.1 ± 0.27, indicating only moderate agreement between the two sets of
readings (Bland & Altman 1986). The
underestimation in MPOD values
yielded by the MPS 9000 is in the
range 0.05–0.15, but only in
approximately 36% of subjects, with
differences between respective measurements ranging from 0.35 to )0.3,
a 0.65 log unit range. It should be
pointed out however that there are a
number of exceptions to the trend for
lower MPOD values on the MPS 9000
compared with the Macular Densitometer. In ﬁve subjects, the MPS
9000 demonstrated higher MPOD values when compared to the Macular
Densitometer (see Fig. 1), and in two
of these cases, the difference is substantial (0.26 and 0.30, respectively).
Clinically, these two cases could not
be discarded as both subjects were
deemed to have understood and per-
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Fig. 3. Bland–Altman plot showing 95% limits of agreement for repeat measures at visit 2 and
visit 3 for the MPS 9000.

formed the MPOD measurement to an
acceptable standard on both devices.
From a statistical viewpoint however,
these may be regarded as outliers. Reanalysis of the data excluding these
two cases does improve the observed
correlation and agreement between
devices to more acceptable levels
(r = 0.778, and the coefﬁcient of
repeatability = 0.20). In other words,
and contrary to the observations of
van der Veen et al. (2009), the observed
discrepancy between instruments is not
systematic and is therefore not amenable to adjustment by means of a correction factor.
Inter-sessional repeatability is an
important consideration for any prospective MP measurement device. The
test–retest variability of the Macular
Densitometer and the MPS 9000 has
been investigated previously (Snodderly et al. 2004; Gallaher et al. 2007;
van der Veen et al. 2009; Bartlett
et al. 2010; De Kinkelder et al. 2011).
The Macular Densitometer has been

shown to demonstrate good test–retest
and intraclass correlation, with a coefﬁcient of variation ranging from 17 to
22% (Snodderly et al. 2004; Gallaher
et al. 2007). The MPS 9000 has also
been reported to exhibit good repeatability, with limits of agreement ranging from 0.15 to 0.18 (van der Veen
et al. 2009; De Kinkelder et al. 2011),
but these results could not be
substantiated in a recent study, which
reported coefﬁcients of repeatability
and reproducibility ranging from 0.25
to 0.33 (Bartlett et al. 2010). The
observed discordance between studies
might be explained, at least in part,
by methodological differences, including the use of more robust, averaged
data in the research setting of the former study (van der Veen et al. 2009),
when compared with data collected in
a manner more reﬂective of a typical
clinical setting in the latter study
(Bartlett et al. 2010).
The mean coefﬁcient of repeatability for the MPS 9000 in the current

study was 0.19 (±0.02), and ranged
from 0.18 to 0.21, which is consistent
with previous ﬁndings (van der Veen
et al. 2009; De Kinkelder et al. 2011),
and has signiﬁcantly better repeatability than that determined by Bartlett
et al. (2010), whose interpretation of
results is somewhat problematic, and
simply not scientiﬁcally justiﬁed or
sustainable. They do, nonetheless, still
suggest a substantial amount of variability between sessions of MPOD
measurement. For the purposes of
comparability, the repeatability of the
Macular Densitometer was also
assessed. The mean coefﬁcient of
repeatability for the Macular Densitometer was 0.12 (±0.01) and ranged
from 0.11 to 0.12, substantially better
than the MPS 9000. Indeed, the range
of MPOD values across all three measures was <0.1 for 92% of subjects
and <0.05 for 44% of subjects, using
the Macular Densitometer, and this
compares with only 54% and 25%,
respectively, for the MPS 9000.
The MPS 9000 device is not
described in sufﬁcient detail in the
published literature to provide a comprehensive analysis of the potential
reasons for the inter-instrument
observed differences in MPOD. Some
of the design features of the instrument could potentially explain the
observed differences. It is not clear,
for example, whether a correction factor has been applied to account for
differences in the spectral output of
the chosen LEDs compared with the
absorption spectrum of MP. The blue
LED peak output for the MPS 9000
is given as 465 nm (van der Veen
et al. 2009, De Kinkelder et al. 2011),
although it is listed as 470 nm in the
product literature. This compares to
MP peak absorption at 458 nm, which
matches the LED output employed in
the Macular Densitometer. If such a
correction factor has been employed
for the MPS 9000, it is not clear
whether this correction is based on
LED manufacturer provided spectral

Table 1. Inter-sessional MPOD variability (mean ± SD) and coefﬁcient of repeatability for the MPS 9000 and Macular Densitometer.
Mean (±SD) MPOD

Coefﬁcient of repeatability

Instrument

Visit 1

Visit 2

Visit 3

Visit 1–visit 2

Visit 2–visit 3

Visit 1–visit 3

MPS 9000
Macular Densitometer

0.31 (±0.15)
0.40 (±0.15)

0.32 (±0.16)
0.38 (±0.16)

0.32 (±0.17)
0.40 (±0.16)

0.18
0.11

0.21
0.12

0.18
0.12

MPOD, macular pigment optical density.
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Fig. 4. Bland–Altman plot showing 95% limits of agreement for repeat measures at visit 2 and
visit 3 for the Macular Densitometer.

outputs or independent spectral analysis of the speciﬁc LED outputs, which
would be preferred. If this correction
has not been applied or has been
incorrectly applied, it certainly could
explain the difference in MP optical
density values derived by the two
devices. Aside from the above
unknown characteristics of the MPS
9000, there are a number of signiﬁcant
differences between the devices and
the respective methodologies, which
may explain both the observed lack of
concordance and the disparity in
terms of inter-sessional repeatability.
The MPS 9000 employs a 1 stimulus for both the central and peripheral
measurements, whereas the Macular
Densitometer employs a 2 stimulus
for the peripheral measurement only
and a 1 target centrally. Invariably,
subjects reported difﬁculty completing
the peripheral measurement, when
using the MPS 9000, whereas no such
difﬁculty was reported for the Macular Densitometer. It is likely that this
difference in peripheral stimulus size is
contributing to the greater relative difﬁculty experienced by subjects using
the MPS 9000 and may explain the
exclusion of three subjects unable to
complete the peripheral measurement
using this instrument. The difference
in eccentricity of the peripheral
reference target (7 for the Macular

Densitometer and 8 for the MPS
9000) could be a potential source of
differences in the derived MP values
(as the calculation of MP is based on
the log ratio of central versus reference values). As the MPS 9000
employs a more eccentric reference
stimulus, it might be expected that
this technique would consequently
derive higher MP values, if the effect
was signiﬁcant. The MPS 9000, however, appears to underestimate MPOD
in comparison with the Macular Densitometer, so it is unlikely that the difference in reference location can
explain the mean difference between
devices.
Another distinction between the
two instruments rests on the role of
subject performance. The Macular
Densitometer affords signiﬁcant control to the subject, who can adjust the
ratio of blue to green until a null
ﬂicker sensation is achieved, without a
time restriction. The subject is simply
instructed to use a method of adjustment or bracketing method to deﬁne
the null ﬂicker zone. The MPS 9000
employs a different technique, where a
suprathreshold ﬂicker rate is gradually
reduced at a set rate of 6 Hz per second, and the subject responds by
pressing a button to indicate the point
at which ﬂicker is detected. The rate
of ﬂicker decrease is a compromise

between testing time and differences
in subject reaction times (van der
Veen et al. 2009). Although reaction
times are known to vary little across
age (Porciatti et al. 1999), response
times are signiﬁcantly more complex.
It would seem reasonable to suggest
that subject threshold criteria could
change during the course of a measurement session, particularly as task
complexity increases from the central
to peripheral target testing (Madden
& Allen 1995; Hommel et al. 2004).
Such a change in response criterion
might not be easily detected by the
examiner and could contribute to
poor results.
Further, the MPS 9000 is unable to
provide a useful measure of subject
performance reliability. The only performance check an examiner can use
is to determine that a ‘typical’
V-shaped ﬂicker response curve is generated.
The
product
literature
describes that ‘irregularities in the
data’ are typical and that the shape of
the curves can vary between individuals. This makes interpretation of the
curve, and reliability of the result,
therefore dependent on examiner skill
and training and subject to signiﬁcant
variation. Indeed, such dependency
could represent a partial explanation
for the poor coefﬁcient of repeatability reported by Bartlett et al. (2010).
It has been suggested that the number
of subjects in the Bartlett paper with
signiﬁcant variation in test–retest
MPOD values represents operator
error (inappropriate acceptance of
low-quality V-shaped ﬂicker response
functions), rather than measurement
noise (Murray et al. 2011). This may
be the case, but if so, this reinforces
the observations herein that MPOD
values obtained using the MPS 9000,
may well be signiﬁcantly affected by
examiner skill level and training, and
furthermore, that the limited means to
determine patient performance acceptability would seem unreliable at best.
The technique basically produces a
single central and peripheral end-point
to determine MPOD. The MPOD
value determined using the Macular
Densitometer by comparison represents the average of multiple (typically
four to six readings) end-points determined by the subject. Variation in
performance, or lack of understanding
of the task, becomes immediately
obvious as a large standard deviation
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in the radiance values produced and
allows the examiner to ensure result
reliability, to a degree that is simply
not achievable with MPS 9000.
The variation in the stimulus-background conﬁguration between instruments is also substantial and certainly
has the potential to induce measurement discrepancies. For the Macular
Densitometer, the conﬁguration is a
short-wave blue background, against
which an incremental blue target is
viewed. For the MPS 9000, the blue
target is viewed against a spectrally
broadband white light surround.
While it is likely that both conﬁgurations effectively suppress the contribution of rods and S-cones, other HFP
methods, such as those used by Beatty
et al. (2000) and Bone & Sparrock
(1971) which have employed a centresurround stimulus conﬁguration, have
been shown to produce a spectral
curve that is best ﬁt with a signiﬁcant
rod contribution (Hammond et al.
2005). Such a centre-surround conﬁguration could potentially suffer retinal
adaptation effects, chromatic aberration effects, and off-axis lens effects
induced by the +5D focusing lens. It
is simply unclear whether the targetstimulus conﬁguration, as employed in
the MPS 9000, fulﬁls the basic principle of any technique for the measurement of MP, namely that such a
technique ‘should provide spectral
absorption curves that match the
extinction spectra of MP’ (Hammond
et al. 2005).
The current study was designed to
evaluate the comparability and repeatability of MPOD measurements, as
determined using the commercial
MPS 9000 in relation to the conventional research standard Macular
Densitometer. It is important to note
that the experimental protocol was
designed to be of clinical relevance
and was compliant with manufacturer
guidelines. The MPS 9000 appears to
provide an unpredictable underestimation of MPOD when compared to the
Macular Densitometer and demonstrates poorer repeatability. Our analysis suggests that the fundamental
principles and technique of the MPS
9000 seem generally robust, but that
the unacceptable test–retest variability
observed here and elsewhere (Bartlett
et al. 2010) may largely be as a consequence of the (i) absence of a userfriendly means to assess subject
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performance variability during the test
procedure, (ii) increased difﬁculty
associated with the peripheral task
and (iii) dependency on examiner
training and skill level. In the
presence of such design features, we
would recommend that best clinical
practice using the MPS 9000 would
require multiple measures of MPOD.
Results should be discarded where
large discrepancies such as those
obtained by Bartlett et al. (2010) are
found and where results are more
consistent, the average MPOD should
be used.
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